Research

The Nvidia and Lilly AI Co-Innovation Lab

Nvidia and Eli Lilly announced an AI co-innovation lab on January 12, 2026, with up to $1 billion over five years, based in the San Francisco Bay Area. What it will do, the compute behind it, and Lilly's other AI deals.

By Ramanath, CTO & Co-Founder at Presenc AI · Last updated: November 2026

Nvidia and Eli Lilly announced an AI co-innovation lab on January 12, 2026 at the J.P. Morgan Healthcare Conference. The two companies said they will jointly invest up to $1 billion over five years in talent, infrastructure and compute. The lab is based in the San Francisco Bay Area, with work expected to begin in South San Francisco in early 2026. As of November 13, 2026, we found no announcement of a formal opening. Coverage in June still described the work as "expected to begin".

Key Facts

ItemDetail
AnnouncedJanuary 12, 2026
InvestmentUp to $1 billion over five years, from both companies together
Split between the companiesNot disclosed
LocationSan Francisco Bay Area. Work to begin in South San Francisco
StaffingLilly scientists working alongside Nvidia model builders and engineers. No headcount given
Software platformNvidia BioNeMo
ComputeInfrastructure intended to use Nvidia's Vera Rubin architecture
Manufacturing toolsNvidia Omniverse libraries and RTX PRO Servers for digital twins of production lines
Opening dateNot announced

The $1 billion is a ceiling on joint spending. It is not a payment from one company to the other, and it is not a licensing deal with milestones like most entries in the AI pharma deal tracker.

What the Lab Is For

  • First project. A continuous learning system that connects Lilly's automated wet labs with computational dry labs, so experiments can run around the clock with a scientist overseeing them.
  • Models. New foundation models for biology and chemistry.
  • Later work. Clinical development, manufacturing and commercial operations, including robotics and digital twins of manufacturing lines.

In the release, Nvidia chief executive Jensen Huang said AI's "most profound impact will be in life sciences". Lilly chief executive David Ricks said the combination "could reinvent drug discovery as we know it".

The Supercomputer Behind It

The lab builds on a Lilly-owned supercomputer announced with Nvidia on October 28, 2025, which Lilly calls an AI factory and has since named LillyPod.

ItemDetail
AnnouncedOctober 28, 2025
SystemNvidia DGX SuperPOD built from DGX B300 systems, described as the first of its kind
GPUs1,016 Nvidia Blackwell Ultra
Stated AI performanceMore than 9,000 petaflops
Go-liveLate February 2026, according to R&D World coverage of a ribbon-cutting
Use by June 2026Running large open-weight language models on site for staff with no token or budget limits, per a post by Lilly's chief AI officer reported by R&D World

Lilly describes it as the most powerful supercomputer in the pharmaceutical industry. Lilly's chief AI officer, Thomas Fuchs, told R&D World in January 2026 that it is "still quite modest" next to the largest AI training clusters.

Lilly's Other AI Deals

DatePartnerTermsScope
January 2024Isomorphic Labs$45M upfront, up to $1.7B in milestonesSmall molecules against multiple targets
June 2024OpenAINot disclosedAntimicrobials for drug-resistant bacteria
September 2025TuneLab, Lilly's own platformNot applicableLets biotech companies use selected Lilly models trained on its proprietary data
Early January 2026Nimbus Therapeutics$55M in upfront and near-term milestones, total up to about $1.3BOral obesity drug
January 2026Chai DiscoveryNot disclosedBiologics design and a model built only for Lilly
March 29, 2026Insilico Medicine$115M upfront, total about $2.75BLicence to preclinical oral drugs and joint programmes

The release also says Nvidia's Clara open models are planned as part of a future TuneLab workflow. For why the "up to" figures in this table are much larger than the upfront payments, see biobucks. For Isomorphic's progress since 2024, see Isomorphic Labs funding and clinical trial status.

Other Nvidia Pharma Work

On the same day as the Lilly announcement, Nvidia announced work with Thermo Fisher Scientific to put its AI into laboratory instruments, according to GEN. Nvidia is also among the organisations named at the launch of OpenAI's GPT-Rosalind model, covered on the OpenAI and Novo Nordisk page.

Methodology

Lab facts and quotes come from the joint Nvidia and Lilly press release of January 12, 2026. Supercomputer specifications come from R&D World's reports of October 2025, January 2026 and June 2026. The Thermo Fisher item is from GEN. Deal terms are sourced on the deal tracker page. Status as of November 13, 2026.

Frequently Asked Questions

Up to $1 billion over five years, invested jointly in talent, infrastructure and compute, according to the January 12, 2026 press release. The companies did not say how the amount is divided between them.
In the San Francisco Bay Area. The press release said work was expected to begin in South San Francisco in early 2026. We found no announcement of a formal opening as of November 13, 2026.
LillyPod is Eli Lilly's own AI supercomputer, announced with Nvidia on October 28, 2025. It is an Nvidia DGX SuperPOD with 1,016 Blackwell Ultra GPUs. R&D World reported that it went live in late February 2026.
A continuous learning system that links Lilly's automated wet labs with computational dry labs for around-the-clock, AI-assisted experiments with a scientist in the loop. Later work is planned in clinical development, manufacturing and commercial operations.
The press release names the BioNeMo platform, the Vera Rubin architecture for the lab's infrastructure, and Omniverse libraries with RTX PRO Servers for digital twins of manufacturing lines.

Hire agents, not agencies.

Presenc is a team of AI agents that builds the pages your buyers search for, and a person checks every one. We take on a few teams at a time.

Request access